Explore Our Biomarker Menu

Biomarker:

ErbB2 (pY1248)

Biological or Clinical Significance:

ERBB2, a known proto-oncogene, is located at the long arm of human chromosome 17 (17q12). Receptor tyrosine-protein kinase erbB-2, also known as CD340 (cluster of differentiation 340), proto-oncogene Neu, Erbb2 (rodent), or ERBB2 (human) is a protein that in humans is encoded by the ERBB2 gene, which is also frequently called HER2 (from human epidermal growth factor receptor 2) or HER2/neu.

HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or overexpression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approximately 30% of breast cancer patients.

References:

  • Mitri Z, Constantine T, O’Regan R (2012). “The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy”. Chemotherapy Research and Practice 2012: 743193. doi:10.1155/2012/743193. PMC 3539433. PMID 23320171.
  • Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U (Dec 1985). “Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene”. Science 230 (4730): 1132–9. doi:10.1126/science.2999974. PMID 2999974.

Analyte:

ErbB2 (pY1248)

Matrix:

Status:

Experienced Running

Sensitivity-LLOQ:

Sensitivity-ULOQ:

platform

MSD-ECL

Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.